KTTA Valuation
Pasithea Therapeutics Corp
$
0.977
- Overview
- Forecast
- Valuation
KTTA Relative Valuation
KTTA's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, KTTA is overvalued; if below, it's undervalued.
Historical Valuation
No Data
Competitors Valuation Multiple
The average P/S ratio for KTTA's competitors is 0.30, providing a benchmark for relative valuation. Pasithea Therapeutics Corp Corp (KTTA) exhibits a P/S ratio of 0.00, which is -100.00% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.
P/S
P/E
EV/EBITDA
EV/EBIT
P/S
People Also Watch
NVDA
NVIDIA Corp
134.380
USD
-0.88%
MSFT
Microsoft Corp
458.320
USD
-0.12%
TSLA
Tesla Inc
343.820
USD
+0.51%
AAPL
Apple Inc
206.860
USD
-0.92%
META
Meta Platforms Inc
637.240
USD
-0.50%
AMZN
Amazon.com Inc
204.070
USD
-1.01%
AVGO
Broadcom Inc
231.690
USD
+0.46%
ORCL
Oracle Corp
160.310
USD
+0.42%
WMT
Walmart Inc
97.800
USD
-0.33%
XOM
Exxon Mobil Corp
104.950
USD
-1.43%
FAQ
Is Pasithea Therapeutics Corp (KTTA) currently overvalued or undervalued?
Pasithea Therapeutics Corp (KTTA) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of 12.18. The fair price of Pasithea Therapeutics Corp (KTTA) is between NaN to NaN according to relative valuation methord.
What is Pasithea Therapeutics Corp (KTTA) fair value?
How does KTTA's valuation metrics compare to the industry average?
What is the current P/B ratio for Pasithea Therapeutics Corp (KTTA) as of May 20 2025?
What is the current FCF Yield for Pasithea Therapeutics Corp (KTTA) as of May 20 2025?
What is the current Forward P/E ratio for Pasithea Therapeutics Corp (KTTA) as of May 20 2025?